This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

RYBELSUS® safety profile

Safety and tolerability of RYBELSUS® have been established in 33 clinical trials in ~20,000 patients across a wide variety of patients populations.
PIONEER clinical trial

Find out more about the Phase 3 clinical trial programme investigating RYBELSUS® (oral semaglutide).
How RYBELSUS® works

By combining semaglutide with the SNAC absorption enhancer, we found a way to deliver a GLP-1 RA in a tablet.

1.

RYBELSUS® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/ S; March 2024.

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

 

The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of March 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.

 

HQ24RYB00041, April 2024